Form 4: Milton C. Ault III Increases Stake in Alzamend Neuro

Director Milton C. Ault III acquired 108,388 shares of Alzamend Neuro, Inc. common stock through Ault Lending, LLC.

Summary

• Director Milton C. Ault III reported the acquisition of 108,388 shares of Alzamend Neuro, Inc. (ALZN) common stock.
• The transaction occurred on April 14, 2026, at a price of $1.0047 per share.
• The shares were acquired indirectly through Ault Lending, LLC, a subsidiary of Hyperscale Data, Inc.
• Following this transaction, the reporting person maintains indirect beneficial ownership of 116,648 shares via Ault Lending, LLC, 11,068 shares via Ault Life Sciences, Inc., and 61 shares via Ault Life Sciences Fund, LLC.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects direct capital commitment from a company director.

Positives

• Insider confidence is demonstrated by the director increasing his indirect equity position in the company.
• The purchase of 108,388 shares indicates a commitment to the issuer's long-term prospects.

Negatives

• None identified in this filing.

Risks

• The filing does not disclose specific operational or market risks, though it notes the reporting person's control over multiple investment vehicles.

Future Outlook

The filing does not contain forward-looking statements regarding company performance or future guidance.

Industry Context

StockSavvy.ai notes that insider buying is generally viewed as a positive signal of management's belief in the company's valuation and future potential, particularly in the volatile biotechnology sector.

Comparison to Industry Standards

• Insider acquisitions are standard practice for directors seeking to align their interests with shareholders.
• The transaction size is consistent with typical director-level equity accumulation in small-cap biotech firms.

Related Party Transactions

• The acquisition was made by Ault Lending, LLC, an entity controlled by the reporting person, Milton C. Ault, III.

Stakeholder Impact

• Shareholders may interpret this purchase as a sign of stability and confidence from the board of directors.

Next Steps

• Continued monitoring of SEC filings for further changes in beneficial ownership by insiders.

Key Dates

Keywords

Alzamend Neuro, ALZN, Insider Trading, Form 4, Milton C. Ault III, Equity Acquisition